These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36933094)

  • 1. The HERA (Hyper-response Risk Assessment) Delphi consensus definition of hyper-responders for in-vitro fertilization.
    Feferkorn I; Ata B; Esteves SC; La Marca A; Paulson R; Blockeel C; Conforti A; Fatemi HM; Humaidan P; Lainas GT; Mol BW; Norman RJ; Orvieto R; Polyzos NP; Santos-Ribeiro S; Sunkara SK; Tan SL; Ubaldi FM; Urman B; Velasco JG; Weissman A; Yarali H; Dahan MH
    J Assist Reprod Genet; 2023 May; 40(5):1071-1081. PubMed ID: 36933094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HERA (Hyper-response Risk Assessment) Delphi consensus for the management of hyper-responders in in vitro fertilization.
    Feferkorn I; Santos-Ribeiro S; Ubaldi FM; Velasco JG; Ata B; Blockeel C; Conforti A; Esteves SC; Fatemi HM; Gianaroli L; Grynberg M; Humaidan P; Lainas GT; La Marca A; Craig LB; Lathi R; Norman RJ; Orvieto R; Paulson R; Pellicer A; Polyzos NP; Roque M; Sunkara SK; Tan SL; Urman B; Venetis C; Weissman A; Yarali H; Dahan MH
    J Assist Reprod Genet; 2023 Nov; 40(11):2681-2695. PubMed ID: 37713144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder.
    Oudshoorn SC; van Tilborg TC; Eijkemans MJC; Oosterhuis GJE; Friederich J; van Hooff MHA; van Santbrink EJP; Brinkhuis EA; Smeenk JMJ; Kwee J; de Koning CH; Groen H; Lambalk CB; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2506-2514. PubMed ID: 29121269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH.
    Lan VT; Linh NK; Tuong HM; Wong PC; Howles CM
    Reprod Biomed Online; 2013 Oct; 27(4):390-9. PubMed ID: 23953069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
    van Tilborg TC; Oudshoorn SC; Eijkemans MJC; Mochtar MH; van Golde RJT; Hoek A; Kuchenbecker WKH; Fleischer K; de Bruin JP; Groen H; van Wely M; Lambalk CB; Laven JSE; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2485-2495. PubMed ID: 29121350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of ovarian reserve markers in IVF clinical practice: a national consensus.
    La Marca A; Ferraretti AP; Palermo R; Ubaldi FM
    Gynecol Endocrinol; 2016; 32(1):1-5. PubMed ID: 26531067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
    Lensen SF; Wilkinson J; Leijdekkers JA; La Marca A; Mol BWJ; Marjoribanks J; Torrance H; Broekmans FJ
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD012693. PubMed ID: 29388198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
    Ngwenya O; Lensen SF; Vail A; Mol BWJ; Broekmans FJ; Wilkinson J
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD012693. PubMed ID: 38174816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization.
    Nardo LG; Gelbaya TA; Wilkinson H; Roberts SA; Yates A; Pemberton P; Laing I
    Fertil Steril; 2009 Nov; 92(5):1586-93. PubMed ID: 18930213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of serum AMH and antral follicle count discrepancy for the prediction of ovarian stimulation response in Poseidon criteria patients.
    Hochberg A; Dahan MH; Yarali H; Vuong LN; Esteves SC
    J Assist Reprod Genet; 2024 Mar; 41(3):717-726. PubMed ID: 38358433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antral follicle count and anti-Müllerian hormone to classify low-prognosis women under the POSEIDON criteria: a classification agreement study of over 9000 patients.
    Esteves SC; Yarali H; Vuong LN; Carvalho JF; Özbek İY; Polat M; Le HL; Pham TD; Ho TM
    Hum Reprod; 2021 May; 36(6):1530-1541. PubMed ID: 33822057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of antral follicle count and serum anti Müllerian hormone level for determination of gonadotropin dosing in in-vitro fertilization: randomized trial.
    Li HWR; Ko JKY; Lee VCY; Yung SSF; Lau EYL; Yeung WSB; Ho PC; Ng EHY
    Ultrasound Obstet Gynecol; 2020 Mar; 55(3):303-309. PubMed ID: 31325336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Associated with Ovarian Hyperstimulation Syndrome (OHSS) Severity in Women With Polycystic Ovary Syndrome Undergoing IVF/ICSI.
    Sun B; Ma Y; Li L; Hu L; Wang F; Zhang Y; Dai S; Sun Y
    Front Endocrinol (Lausanne); 2020; 11():615957. PubMed ID: 33542709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET.
    Tsakos E; Tolikas A; Daniilidis A; Asimakopoulos B
    Arch Gynecol Obstet; 2014 Dec; 290(6):1249-53. PubMed ID: 25001569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose Nomogram of Individualization of the Initial Follicle-Stimulating Hormone Dosage for Patients with Polycystic Ovary Syndrome Undergoing IVF/ICSI with the GnRH-Ant Protocol: A Retrospective Cohort Study.
    Si M; Qi X; Zhen X; Yang C; Tian T; Long X; Qiao J
    Adv Ther; 2023 Sep; 40(9):3971-3985. PubMed ID: 37395872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone.
    Lauritsen MP; Bentzen JG; Pinborg A; Loft A; Forman JL; Thuesen LL; Cohen A; Hougaard DM; Nyboe Andersen A
    Hum Reprod; 2014 Apr; 29(4):791-801. PubMed ID: 24435776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordance between serum anti-Müllerian hormone concentrations and antral follicle counts: not only technical issues.
    Alebic MŠ; Stojanovic N; Dewailly D
    Hum Reprod; 2018 Jun; 33(6):1141-1148. PubMed ID: 29688494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum AMH Level to Predict the Hyper Response in Women with PCOS and Non-PCOS Undergoing Controlled Ovarian Stimulation in ART.
    Vembu R; Reddy NS
    J Hum Reprod Sci; 2017; 10(2):91-94. PubMed ID: 28904496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The physiology and clinical utility of anti-Mullerian hormone in women.
    Dewailly D; Andersen CY; Balen A; Broekmans F; Dilaver N; Fanchin R; Griesinger G; Kelsey TW; La Marca A; Lambalk C; Mason H; Nelson SM; Visser JA; Wallace WH; Anderson RA
    Hum Reprod Update; 2014; 20(3):370-85. PubMed ID: 24430863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.